Validations: Nitrosamine Risk Assessment & Control Strategy
System Suitability for Nitrosamine Methods The emergence of nitrosamines in pharmaceutical products has prompted a rigorous response from regulatory agencies such as the US FDA, EMA, and MHRA. This article focuses on the systematic assessment of analytical methods specifically designed to quantify nitrosamines, highlighting the necessity of establishing system suitability parameters for robustness and compliance. By adhering to the guidelines…
Inspection Storyboards for Nitrosamine Risk Ranking Inspection Storyboards for Nitrosamine Risk Ranking Introduction to Nitrosamine Risk Assessment The detection and quantification of nitrosamine impurities in pharmaceuticals are critical in ensuring patient safety and regulatory compliance. As healthcare professionals navigate the landscape of nitrosamine risk assessment, understanding the implications of NDMA limits imposed by regulatory authorities such as the US FDA…
Analytical Strategies for Nitrosamines: LC-MS/MS vs GC-MS Analytical Strategies for Nitrosamines: LC-MS/MS vs GC-MS In recent years, the discovery of nitrosamines in pharmaceutical products has raised significant concerns among regulatory authorities and pharmaceutical manufacturers. Addressing these concerns requires a robust approach to risk assessment and control strategies. This article aims to provide a comprehensive guide on the analytical methods used…
Method Sensitivity vs Limits: NDMA and NDEA Detection Targets Method Sensitivity vs Limits: NDMA and NDEA Detection Targets The growing concern surrounding nitrosamines in pharmaceuticals has led to an increase in regulatory scrutiny and the need for robust analytical methods to assess their presence and quantification. Among the most prominent nitrosamines affecting pharmaceutical products are N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA)….
Surrogate Standards and Isotopically Labeled IS: When and How Surrogate Standards and Isotopically Labeled IS: When and How Introduction to Surrogate Standards and Isotopically Labeled Internal Standards The pharmaceutical industry is facing increasing scrutiny regarding nitrosamine contaminants in drug products, particularly those containing active pharmaceutical ingredients (APIs) that may incorporate nitrosamines during manufacturing. As regulatory boundaries tighten globally, effective nitrosamine…
Data Integrity for Risk Files: Audit Trails and Versioning Data Integrity for Risk Files: Audit Trails and Versioning In the pharmaceutical industry, ensuring data integrity within risk files is critical for maintaining compliance and safeguarding product quality. This is especially true in the context of nitrosamine risk assessment, where stringent regulations demand robust documentation, effective audit trails, and proper versioning…
Timing & Cadence: How Often to Re-Rank Timing & Cadence: How Often to Re-Rank Introduction to Nitrosamine Risk Assessment Nitrosamines have garnered significant attention in the pharmaceutical industry due to their potential carcinogenic effects. Regulatory authorities such as the US FDA and the EMA have established Guidance Documents outlining the methodologies and expectations for nitrosamine risk assessment. It is crucial…
High-Risk Suppliers: Oversight, Audits, and Remediation High-Risk Suppliers: Oversight, Audits, and Remediation Introduction to High-Risk Suppliers in the Pharmaceutical Industry The increasing scrutiny over nitrosamine contamination has led to a heightened need for robust risk assessments and compliance strategies regarding high-risk suppliers. This article outlines a step-by-step tutorial aimed at pharmaceutical professionals to enhance their understanding of nitrosamine risk assessments…
Bridging After Changes: Supplier, Route, or Site In the landscape of pharmaceutical manufacturing, the introduction of nitrosamines has raised fundamental challenges regarding safety and compliance. Regulators in the US, EU, and UK emphasize the importance of rigorous nitrosamine risk assessment and management strategies. This article presents a comprehensive guide to bridging operations after changes involving suppliers, routes, or manufacturing sites…
Top Risk Ranking Mistakes—and How to Avoid Them Top Risk Ranking Mistakes—and How to Avoid Them Introduction to Nitrosamine Risk Assessment Nitrosamines pose a significant threat to the safety and efficacy of pharmaceutical products. The recent focus on nitrosamine impurities, specifically N-nitrosodimethylamine (NDMA), has prompted regulatory authorities such as the FDA and European Medicines Agency (EMA) to issue guidelines on…